The rush for research
More than 5 million Americans live with Alzheimerโs disease, a figure thatโs expected to double by 2060, according to theย CDC. Itโs the sixth-leading cause of death in the United States.
Medical experts are hoping to change those statistics. More than 400 experimental treatments are now in U.S. clinical trials for Alzheimerโs. โWe desperately need an answer,โ says Heather Snyder, PhD, senior director of medical and scientific operations at the Alzheimerโs Association. โEvery idea should be explored for a way to stop or slow the progression of the disease.โ There are currently five FDA-approved Alzheimerโs drugs, which temporarily boost theย performance of brain chemicals and slow memory decline for a short period of time. But they donโt treat the underlying decline and death of brain cells. Scientists are hopeful that one of the following areas of research may lead to a solution that will. Stop believing these 15 myths about Alzheimer’s.
New tests to catch Alzheimerโs early
At the moment, positron emission tomography imaging (PET scans) or invasive tests like sampling your cerebrospinal fluid are the only ways to catch Alzheimerโs in its early stages. But researchers have been developing blood tests that can detect amyloid beta, a toxic protein that forms the brain plaque associated with Alzheimerโs disease.
Scientists from Germany and Sweden analyzed archived blood that was collected between July 2000 and December 2002 in a study of adults ages 50 to 75. The researchers then compared the samples from adults who were later diagnosed with Alzheimerโs with those from people who didn’t develop the disease. The new test correctly identified those with Alzheimer’s in almost 70ย percent of cases. Even better, this test could have spotted the disease up to eight years earlier. Another study produced a blood test that could spot Alzheimerโs even soonerโup to 20 years before diagnosis.
Even though a blood test wonโt cure Alzheimerโs, it could help researchers develop treatments designed to slow the progress of the disease by identifying at-risk patients before too much damage has occurred. More work needs to be done to advance the treatment, but some researchers are hopeful that the blood test will be readily available to the public within a few years. Don’t ignore these 10 early signs of Alzheimer’s disease.
Promising new drugs
Even in the age of modern medicine, most new drugs and treatments for Alzheimer’s fail. Which is why experts are cautiously optimistic about something called BAN2401: Not only does this antibody reduce amyloid brain plaques, but it also slows cognitive decline. In the study, the New York Times reports, researchers gave 856 patients from the United States, Japan, and Europe injections of BAN2401. Doctors had previously diagnosed the patients with either mild cognitive impairment or mild Alzheimerโs dementia; they all had large amounts of amyloid beta in their brains. Only 161 patients were injected with the highest of the five doses of BAN2401โevery two weeks for 18 months. In the highest-dose group, 81 percent showed significant drops in their amyloid levels. While their cognitive skills still declined, they did so at a rate that was 30 percent slower than the placebo groupโs rate of decline.
More trials are needed to truly determine the drugโs effectiveness and safety before the FDA gives its stamp of approval for Alzheimerโs patients. A similar treatment, aducanumab, is in early trials and appears to do the same thing as BAN2401, but those clinical results wonโt be available until 2020, according to the New York Times.
Understanding tau tangles
Tau is a protein in the brain that can twist into microscopic fibers called tangles. When this happens, cells die because nutrients can no longer move through them; the brainโs transport systems eventually disintegrate. โTau tangles are not unique to Alzheimerโs disease,โ says Snyder. โTau clumps in other brain diseases, like Parkinsonโs disease dementia, so itโs being researched in other communities as well.โ
Fortunately, scientists from theย University of Texas Southwesternโs OโDonnell Brain Institute have just discovered how and when a healthy tau protein becomes toxicโwhat the study authors call the โBig Bangโ of Alzheimerโs disease. The researchers found that a tiny portion of the toxic tau protein that is normally folded inside actually sticks out, and that causes it to connect and tangle with other tau proteins. โThe hunt is on to build on this finding and make a treatment that blocks the neurodegeneration process where it begins,โ Marc Diamond, MD, director for UT Southwesternโs Center for Alzheimerโs and Neurodegenerative Diseases,ย told UT Southwestern Medical Center. Learn the differences between Alzheimer’s and dementia.
New Alzheimerโs genes
Scientists have also been looking into a possible genetic component behind Alzheimerโs diseaseโit does tend to run in families, after all. In one study, researchers from Boston University and the Alzheimerโs Disease Sequencing Project analyzed entire genetic sequences in nearly 6,000 people with Alzheimerโs disease, which they compared with the genes of 5,000 healthy older adults. The result? They found several rare gene variations that they believe could be linked to Alzheimerโs disease. The study authors believe that an inflammatory response in the body could trigger changes in the genes, and that could lead to brain degeneration. More research is necessary to get the whole genetic picture, but the research is promising.
Other research suggests that inheriting just one variant copy of the apolipoprotein E (APOE) gene can double your risk for Alzheimerโs disease, according to the Harvard Heart Letter. Researchers believe that the e4 variant interferes with body defenses that would block the growth of amyloid beta plaques. The only issue: Sixty percent of people who suffer from Alzheimerโs don’t have the e4 variant. โIdentifying rare variants could enhance our ability to find novel therapeutic targets and advance precision medicine approaches for Alzheimer’s disease,โ Eliezer Masliah, MD, director of the Division of Neuroscience at the National Institute on Aging,ย said in a press release.ย Make sure you know these 15 things no one tells you about Alzheimer’s.
Repurposing other medications
Itโs possible that we already have drugsโapproved to treat other conditionsโthat could block Alzheimerโs. One example: Yale University School of Medicine researchers found that an experimental cancer drug, saracatinib, restored memory loss and reversed brain problems in mice; they are now testing it in humans. โThey are investigating a pathway that results in the activation of a protein called Fyn kinase,โ says Snyder. This protein plays a major role in how clusters of beta-amyloid damage brain cellsโand the cancer drug seems to block Fyn kinase. The research team recently finished collecting data on its safety, tolerability, and effectiveness in treating Alzheimerโs. A total of 159 participants received either saracatinib or a placebo for one year. The results have yet to be released.
Looking outside the brain for early Alzheimerโs disease clues
Your brain may not be the only target of Alzheimerโs disease: Researchers from Cedars-Sinai Medical Center in Los Angeles used eye-imaging technology to analyze the retinas of a small group of Alzheimerโs patients. In the study,ย the Alzheimerโs patients had 4.7 times more amyloid beta in their eyes than the people who did not have the disease.
Another study revealed that people with rosacea (a skin condition that causes facial redness) are 7 percent more likely to develop some form of dementia and 25 percent more likely to develop Alzheimerโs disease. The inflammation of rosaceaโand the proteins involvedโmay contribute to the development of Alzheimer’s, the study authors say. Now check out 50 everyday habits that reduce your risk of Alzheimer’s and dementia.